Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Pancreatic Ductal Adenocarcinoma × Albumin-Bound Paclitaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 5 Carcinoma, Non-Small-Cell Lung 3 Breast Neoplasms 3 Triple Negative Breast Neoplasms 2 Ovarian Neoplasms 2 Melanoma 2 Solid Tumor 1 Sarcoma 1 Recurrent Bladder Urothelial Carcinoma 1 Prostatic Neoplasms 1 Pancreatic Ductal Adenocarcinoma 1 Neoplasm Metastasis 1 Endometrial Neoplasms 1 Cholangiocarcinoma 1 Advanced Breast Cancer 1

Interventions

sonidegib 1 devimistat 1 PEGPH20 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04134468 2020-01-31

MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma

Abramson Cancer Center at Penn Medicine

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡